Literature DB >> 26050621

Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.

L O'Leary1, A M van der Sloot2,3, C R Reis4, S Deegan1, A E Ryan5, S P S Dhami1, L S Murillo6, R H Cool4, P Correa de Sampaio7, K Thompson8, G Murphy7, W J Quax4, L Serrano2, A Samali1, E Szegezdi1.   

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a death ligand cytokine known for its cytotoxic activity against malignantly transformed cells. TRAIL induces cell death through binding to death receptors DR4 and DR5. The inhibitory decoy receptors (DcR1 and DcR2) co-expressed with death receptor 4 (DR4)/DR5 on the same cell can block the transmission of the apoptotic signal. Here, we show that DcRs also regulate TRAIL sensitivity at a supracellular level and thus represent a mechanism by which the microenvironment can diminish tumour TRAIL sensitivity. Mathematical modelling and layered or spheroid stroma-extracellular matrix-tumour cultures were used to model the tumour microenvironment. By engineering TRAIL to escape binding by DcRs, we found that DcRs do not only act in a cell-autonomous or cis-regulatory manner, but also exert trans-cellular regulation originating from stromal cells and affect tumour cells, highlighting the potent inhibitory effect of DcRs in the tumour tissue and the necessity of selective targeting of the two death-inducing TRAIL receptors to maximise efficacy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26050621     DOI: 10.1038/onc.2015.180

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

Review 1.  Viruses and apoptosis.

Authors:  A Roulston; R C Marcellus; P E Branton
Journal:  Annu Rev Microbiol       Date:  1999       Impact factor: 15.500

2.  Apoptosis and mammary gland involution: reviewing the process.

Authors:  P A Furth; U Bar-Peled; M Li
Journal:  Apoptosis       Date:  1997       Impact factor: 4.677

3.  High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.

Authors:  M E D Chamuleau; G J Ossenkoppele; A van Rhenen; L van Dreunen; S M G Jirka; A Zevenbergen; G J Schuurhuis; A A van de Loosdrecht
Journal:  Leuk Res       Date:  2011-02-01       Impact factor: 3.156

4.  Barriers to effective TRAIL-targeted therapy of malignancy.

Authors:  Martin J S Dyer; Marion MacFarlane; Gerald M Cohen
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

5.  Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

Authors:  Almer M van der Sloot; Vicente Tur; Eva Szegezdi; Margaret M Mullally; Robbert H Cool; Afshin Samali; Luis Serrano; Wim J Quax
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

6.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

Review 7.  Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion.

Authors:  Sarah Shirley; Alexandre Morizot; Olivier Micheau
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-09       Impact factor: 4.169

8.  Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.

Authors:  Eva Szegezdi; Almer M van der Sloot; Devalingam Mahalingam; Lynda O'Leary; Robbert H Cool; Inés G Muñoz; Guillermo Montoya; Wim J Quax; Steven de Jong; Afshin Samali; Luis Serrano
Journal:  Mol Cell Proteomics       Date:  2012-01-02       Impact factor: 5.911

9.  Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways.

Authors:  M van Dijk; A Halpin-McCormick; T Sessler; A Samali; E Szegezdi
Journal:  Cell Death Dis       Date:  2013-07-04       Impact factor: 8.469

10.  Targeting AML through DR4 with a novel variant of rhTRAIL.

Authors:  Eva Szegezdi; Carlos R Reis; Almer M van der Sloot; Alessandro Natoni; Aoife O'Reilly; Janice Reeve; Robbert H Cool; Michael O'Dwyer; Steven Knapper; Luis Serrano; Wim J Quax; Afshin Samali
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

View more
  25 in total

Review 1.  Major apoptotic mechanisms and genes involved in apoptosis.

Authors:  Yağmur Kiraz; Aysun Adan; Melis Kartal Yandim; Yusuf Baran
Journal:  Tumour Biol       Date:  2016-04-09

2.  Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.

Authors:  Lei Miao; Qi Liu; C Michael Lin; Cong Luo; Yuhua Wang; Lina Liu; Weiyan Yin; Shihao Hu; William Y Kim; Leaf Huang
Journal:  Cancer Res       Date:  2016-11-18       Impact factor: 12.701

3.  Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5.

Authors:  Xin Hua; Peng Wu; Guo-Sheng Gao; Xiao-Lei Ye
Journal:  Int J Ophthalmol       Date:  2021-12-18       Impact factor: 1.779

4.  Generation of Tumour-stroma Minispheroids for Drug Efficacy Testing.

Authors:  Mark Watters; Eva Szegezdi
Journal:  Bio Protoc       Date:  2017-01-05

Review 5.  Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.

Authors:  Kelly Xue Jing Jong; Elsa Haniffah Mejia Mohamed; Zaridatul Aini Ibrahim
Journal:  Apoptosis       Date:  2022-10-07       Impact factor: 5.561

6.  3-Dimensional Model to Study Apoptosis Induction of Activated Natural Killer Cells Conditioned Medium Using Patient-Derived Colorectal Cancer Organoids.

Authors:  Benyamin Parseh; Ayyoob Khosravi; Abdolreza Fazel; Jafar Ai; Somayeh Ebrahimi-Barough; Javad Verdi; Majid Shahbazi
Journal:  Front Cell Dev Biol       Date:  2022-05-26

7.  An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Authors:  Martin Siegemund; Oliver Seifert; Maria Zarani; Tamara Džinić; Valentino De Leo; Doris Göttsch; Sabine Münkel; Meike Hutt; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2016-04-11       Impact factor: 5.857

Review 8.  Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.

Authors:  Ufuk Mert; Ahter Dilsad Sanlioglu
Journal:  Cell Mol Life Sci       Date:  2016-08-10       Impact factor: 9.261

9.  Physical tuning of galectin-3 signaling.

Authors:  Shaheen A Farhadi; Renjie Liu; Matthew W Becker; Edward A Phelps; Gregory A Hudalla
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 11.205

10.  An added dimension to tumour TRAIL sensitivity.

Authors:  Sandra Healy; Lynda O'Leary; Eva Szegezdi
Journal:  Oncoscience       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.